The interaction between prognostic and pharmacodynamic biomarkers

被引：0
|
作者：
Bouranis, L. [1 ]
Sperrin, M. [1 ]
Greystoke, A. [2 ]
Dive, C. [2 ]
Renehan, A. G. [2 ,3 ]
机构：
[1] Univ Lancaster, Fylde Coll, Dept Math & Stat, Lancaster, England
[2] Univ Manchester, Paterson Inst Canc Res, Clin & Expt Pharmacol CEP Grp, Manchester, Lancs, England
[3] Univ Manchester, Fac Inst Canc Sci, Manchester, Lancs, England
来源：
BRITISH JOURNAL OF CANCER | 2013年 / 109卷 / 07期
基金：
英国医学研究理事会;
关键词：
EARLY CLINICAL-TRIALS; CIRCULATING BIOMARKERS; VALIDATION; CANCER; GUIDELINES; LYMPHOMA;
D O I：
10.1038/bjc.2013.527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention. Methods: Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy. Results: The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker. Conclusion: These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions.
引用
收藏
页码：1782 / 1785
页数：4
相关论文
共 50 条
  • [1] The interaction between prognostic and pharmacodynamic biomarkers
    L Bouranis
    M Sperrin
    A Greystoke
    C Dive
    A G Renehan
    British Journal of Cancer, 2013, 109 : 1782 - 1785
  • [2] Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
    Benatar, Michael
    Zhang, Lanyu
    Wang, Lily
    Granit, Volkan
    Statland, Jeffrey
    Barohn, Richard
    Swenson, Andrea
    Ravits, John
    Jackson, Carlayne
    Burns, Ted M.
    Trivedi, Jaya
    Pioro, Erik P.
    Caress, James
    Katz, Jonathan
    McCauley, Jacob L.
    Rademakers, Rosa
    Malaspina, Andrea
    Ostrow, Lyle W.
    Wuu, Joanne
    NEUROLOGY, 2020, 95 (01) : E59 - E69
  • [3] Pharmacodynamic interaction between ezetimibe and rosuvastatin
    Kosoglou, T
    Statkevich, P
    Yang, B
    Suresh, R
    Zhu, Y
    Maxwell, SE
    Tiessen, R
    Cutler, DL
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 153 - 153
  • [4] Pharmacodynamic interaction between ezetimibe and rosuvastatin
    Kosoglou, T
    Statkevich, P
    Yang, B
    Suresh, R
    Zhu, YL
    Boutros, T
    Maxwell, SE
    Tiessen, R
    Cutler, DL
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (08) : 1185 - 1195
  • [5] PHARMACODYNAMIC INTERACTION BETWEEN ALPIDEM AND LORAZEPAM
    PATAT, A
    PERRAULT, MC
    VANDEL, B
    ZIELENIUK, I
    BROHIER, S
    MORSELLI, PL
    ROSENZWEIG, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 134 - 134
  • [6] A PHARMACODYNAMIC INTERACTION BETWEEN CAFFEINE AND PHENYLPROPANOLAMINE
    BROWN, NJ
    RYDER, D
    BRANCH, RA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (04) : 363 - 371
  • [7] A pharmacodynamic interaction between ciprofloxacin and cyclosporin
    Reactions Weekly, 1997, 677 (1) : 4 - 4
  • [8] PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN FUROSEMIDE AND METOLAZONE
    MARONE, C
    MUGGLI, F
    FREY, FJ
    KIDNEY INTERNATIONAL, 1985, 28 (03) : 596 - 596
  • [9] Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe
    Kosoglou, T
    Statkevich, P
    Fruchart, JC
    Pember, LJC
    Reyderman, L
    Cutler, DL
    Guillaume, M
    Maxwell, SE
    Veltri, EP
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (08) : 1197 - 1207
  • [10] PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN CARBARYL AND CIMETIDINE
    MAY, DG
    WARD, SA
    NAUKAM, RJ
    KAMBAM, JR
    HEATH, AJ
    BRANCH, RA
    VETERINARY AND HUMAN TOXICOLOGY, 1988, 30 (04) : 363 - 363
12345